This investment will accelerate the development of NanoSyrinx’s technology platform, which focuses on creating biologic treatments aimed at previously ‘undruggable’ intracellular targets. Additionally, the company has appointed Dr Edwin Moses as Chairman of the Board of Directors.

The funding round was co-led by BGF, Octopus Ventures, and M Ventures, with continued support from existing investors IQ Capital and Meltwind. Global pharmaceutical giant Eli Lilly and Company also participated in the round. NanoSyrinx plans to use the funds to advance its nanosyringe platform, which is designed to selectively deliver peptide and protein therapeutics – such as gene editors and enzymes – directly into the cytosol of targeted cells.

Dr Moses, a highly respected figure in the life sciences sector, succeeds Stephen Taylor as Chairman. With over 30 years of board-level experience across 20 life science companies, Moses has been instrumental in scaling biotech firms and leading successful exits. He is currently Chairman of Achilles Therapeutics, LabGenius, and Avantium, and previously served as CEO of Ablynx NV, which was acquired by Sanofi for $4.8 billion, and Oxford Asymmetry International, which was sold to Evotec for £316 million. His leadership in taking companies public on major exchanges such as the London Stock Exchange, EuroNext, and NASDAQ has resulted in raising over €700 million in equity and debt financing.

With Moses at the helm, NanoSyrinx aims to maximise the potential of its nanosyringe platform, leveraging both in-house pipeline development and strategic commercial partnerships to advance its intracellular therapeutic capabilities.

Dr Joe Healey, Chief Executive Officer, NanoSyrinx said: “Edwin has significant experience as a successful CEO and Chairman, with extensive involvement in biotech fundraising, strategic commercial partnerships and successful exits. We are thrilled to have him joining as Chair of our Board as we drive forward with our ambitious plans. He joins us at a pivotal stage alongside this financing, which places us in a well-capitalised position to further develop our intracellular drug delivery technology to realise its full potential in developing medicines. We would like to thank Steve for all his help over the years, and recognise the instrumental part he has played in getting the company to where it is today.”

Dr Edwin Moses, Chairman, NanoSyrinx commented: “NanoSyrinx’s technology promises to make a tremendous positive difference to the very challenging problem of intracellular delivery of therapeutics.  I am delighted to join the Board and help build on the momentum of this latest fundraise, to support the Company and its leadership team in the further development of this unique platform which has the potential to create enormous value and make a real difference to patients’ lives.”

Lucy Edwardes Jones, Investor at BGF said: “While huge advances have been made in the field of biologic therapies, the delivery challenge remains a key bottleneck. We are excited by the potential of NanoSyrinx’s unique technology to unlock this, enabling promising new drugs to reach previously inaccessible disease targets in the body. We are looking forward to working closely with Edwin, the team and our co-investors to see this exciting technology through to impact.”